Substances · Arylcyclohexylamines
FXE (Fluorexetamine)
- Preferred name
- FXE (Fluorexetamine)
- IUPAC name
- 2-(ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one
- Parent CAS number (reference)
- 2850352-64-4
- Molecular formula
- C14H18FNO
- Molecular weight
- 235.3 g/mol
- InChIKey
- FCETYWCLCUZFJI-UHFFFAOYSA-N
- PubChem
- CID 137332183
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
Fluorexetamine 3-F-2'-oxo-PCE FXE
Verified Neurochemical & Toxicological Intelligence
FXE (Fluorexetamine)
Receptor Telemetry & Mechanism of Action
Fluorexetamine acting as a brisk, clear-headed NMDA channel blocker intermediate in potency between 2-FDCK and DMXE.
Biotransformation & Active Metabolites
N-deethylation via hepatic CYP enzymes.
Temporal Pharmacokinetics
3-Fluoro-2'-oxo-PCE Dissociative (NMDA Antagonist) — More energetic and colorful than 2-FDCK while shorter and cleaner on recovery than O-PCE or DCK.
- Onset 15–35 min
- Peak Window 1–2 h
- Total Window 2.5–4.5 h
- Residual / Half-Life 2–5 h residual
More energetic and colorful than 2-FDCK while shorter and cleaner on recovery than O-PCE or DCK.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
10–20 mg
Subtle threshold receptor activity (3-Fluoro-2'-oxo-PCE Dissociative (NMDA Antagonist)).
Minimal baseline autonomic shift.
20–40 mg
Mild, clear-headed expression of primary class profile.
Light somatic modulation.
40–75 mg
Full characteristic neurochemical and perceptual profile documented in literature.
Moderate somatic relaxation, ataxia, or autonomic tone depending on class.
75–110 mg
Pronounced intensity, cognitive/motor impairment, or deep immersion.
Marked somatic load and heightened adverse-event sensitivity.
120+ mg
Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.
High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Severe ataxia, unconsciousness, respiratory depression, and fatal vomiting aspiration.
Elevated Hazard — Avoid
Compounds hypertension, tachycardia, manic disorientation, and psychotic episodes.
Caution / Receptor Attenuation
Dramatically intensifies dissociation, confusion, and sensory immersion.
Structural Isomer & Sibling Comparison
More energetic and colorful than 2-FDCK while shorter and cleaner on recovery than O-PCE or DCK.
Physicochemical Stability & Storage
Physical Form: White to off-white crystalline powder or fine crystals. · Soluble in water, ethanol, and saline.
Chemically stable when kept dry, sealed, and protected from light at room temperature.
Cross-Tolerance & Dependence Profile
Slowly decaying NMDA cross-tolerance shared across all arylcyclohexylamines (halves in ~3–7 days, full baseline 2+ weeks). Chronic frequent exposure carries documented urological/bladder epithelial toxicity.
Codes on this card
Short meanings for the abbreviations printed with this substance.
DAT
Dopamine transporter
DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.
SERT
Serotonin transporter
SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.
NMDA
NMDA glutamate channel
NMDA is a glutamate receptor that works like a gated channel. Ketamine-type and PCP-type cards cite it when papers describe that channel as blocked.
EC₅₀ / IC₅₀
Halfway concentration
EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.
Kᵢ
Binding tightness in nanomoles
Ki says how tightly a compound sits on a receptor in a binding test. It is written in nanomoles per litre. A Ki of 1 nM means very tight binding in that experiment.
ratio
Selectivity ratio
A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.
T½
Half-life
Half-life is the time it takes a measured concentration to fall by half. After one half-life, half remains. After another, a quarter of the original measurement remains.
Tolerancja ×
Cross-Tolerance
When exposure to one compound reduces sensitivity to other compounds that act on the same receptor family (for example across all 5-HT2A lysergamides or all GABA-A modulators).
Chemical Architecture & Structural Profile
FXE (Fluorexetamine) (2-(ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one) is a reference compound belonging to the Arylcyclohexylamines class, characterized by the molecular formula C14H18FNO and a molar mass of 235.3 g/mol. The parent molecule is indexed under CAS registry number 2850352-64-4 and in the NCBI PubChem database as CID 137332183 (Standard InChIKey: FCETYWCLCUZFJI-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), FXE (Fluorexetamine) is indexed within the Arylcyclohexylamines structural group. Arylcyclohexylamine derivative; toxicological literature highlights severe hazard interactions when combined with central nervous system depressants (alcohol, GHB/GBL, opioids, benzodiazepines). Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Riksdagen — Förordning (1999:58) om förbud mot vissa hälsofarliga varor — Sveriges riksdag (2026-11-12)